OECD Home › Directorate for Science, Technology and Industry › Biotechnology policies › Latest Documents
The focus at the OECD on industrial biotechnology is to identify the potential contribution of biotechnology to sustainable growth and development, and identify and appraise policy options for supply and demand side interventions that can drive efficient transition towards bio-based economy.
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
English, , 849kb
The 2006 edition OECD Biotechnology Statistics includes data for 23 OECD countries and two observer countries, plus China (Shanghai), and takes a major step forward in improving the comparability of biotechnology indicators among countries.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.
These guidelines offer principles and best practices for the licensing of genetic inventions used for the purpose of human health care.
While many countries have invested in the production of health technology assessment, evidence about its use in decision making is limited. This report analyses the barriers to, and facilitators of, evidence-based decision making in OECD health-care systems.
This workshop brought together a wide range of stakeholders, including officials of regulatory agencies, representatives of relevant regional or international organizations, researchers, patients’ organizations and representative from industry.